These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 2050167)

  • 41. Disposition and absolute bioavailability of furosemide in healthy males.
    Waller ES; Hamilton SF; Massarella JW; Sharanevych MA; Smith RV; Yakatan GJ; Doluisio JT
    J Pharm Sci; 1982 Oct; 71(10):1105-8. PubMed ID: 7143205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of furosemide after oral administration to horses.
    Johansson AM; Gardner SY; Levine JF; Papich MG; Lafevers DH; Goldman RB; Sheets MK; Atkins CE
    J Vet Intern Med; 2004; 18(5):739-43. PubMed ID: 15515593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological properties of the novel highly potent diuretic 7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinone 4-oxime-O-sulfonic acid potassium salt.
    Shinkawa T; Yamasaki F; Kikuchi A; Nakakuki M; Nishijima K; Uemura A; Mizota M; Orita Y
    Arzneimittelforschung; 1992 Dec; 42(12):1466-72. PubMed ID: 1337698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
    González G; Arancibia A; Rivas MI; Caro P; Antezana C
    Eur J Clin Pharmacol; 1982; 22(4):315-20. PubMed ID: 7106167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
    Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
    Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius).
    Ali BH; Wong YC; Alhadrami GA; Charles BG; Bashir AK
    Res Vet Sci; 1998; 64(1):69-72. PubMed ID: 9557809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Furosemide absorption in patients with cirrhosis.
    Fredrick MJ; Pound DC; Hall SD; Brater DC
    Clin Pharmacol Ther; 1991 Mar; 49(3):241-7. PubMed ID: 2007318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bumetanide and furosemide.
    Brater DC; Chennavasin P; Day B; Burdette A; Anderson S
    Clin Pharmacol Ther; 1983 Aug; 34(2):207-13. PubMed ID: 6872415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.
    Hammarlund MM; Paalzow LK; Odlind B
    Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs.
    Hori Y; Katou A; Tsubaki M; Kanai K; Nakao R; Hoshi F; Itoh N; Higuchi S
    Am J Vet Res; 2008 Dec; 69(12):1664-9. PubMed ID: 19046016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gender effect on diuretic response to hydrochlorothiazide and furosemide.
    Franson KL; Kuk JM; Lam NP; Lau AH
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):101-5. PubMed ID: 8705087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of ciprofloxacin in cystic fibrosis.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Heggen L; Stempel D; Smith AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):915-9. PubMed ID: 3619423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.
    Kim SH; Choi YM; Lee MG
    J Pharmacokinet Biopharm; 1993 Feb; 21(1):1-17. PubMed ID: 8410679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of furosemide on water and sodium excretion in apparently normal infants].
    López Uriarte A; Sánchez Burgos J; Santos Atherton D
    Bol Med Hosp Infant Mex; 1976; 33(3):693-8. PubMed ID: 1275971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P
    Scand J Urol Nephrol Suppl; 1988; 111():1-66. PubMed ID: 3201162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Altered prednisolone pharmacokinetics in patients with cystic fibrosis.
    Dove AM; Szefler SJ; Hill MR; Jusko WJ; Larsen GL; Accurso FJ
    J Pediatr; 1992 May; 120(5):789-94. PubMed ID: 1578318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.